Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials

Pooling randomized trials of patients with reduced kidney function (eGFR below 60), GLP-1 receptor agonists lowered the risk of kidney disease progression, cardiovascular events, and death.